A new study from Mayo Clinic researchers suggests that GLP-1 receptor agonists, medications commonly used for diabetes and weight loss, may also reduce the risk of kidney failure in adults with bipolar disorder and chronic kidney disease. Published in the Journal of Affective Disorders, the findings highlight a potential secondary benefit for a high-risk group.
People with bipolar disorder face raised rates of chronic kidney disease due to factors like obesity, diabetes, and high blood pressure. Some psychiatric treatments, including lithium, further strain kidney function, requiring regular monitoring. GLP-1 drugs, originally developed for type 2 diabetes, have shown kidney-protective effects in other populations, prompting researchers to investigate their impact on bipolar patients.
The study analyzed de-identified health records from 131 million adults across 117 health systems, focusing on those with the condition and mild-to-moderate kidney disease. Participants who started GLP-1 medications were compared to two reference groups: individuals receiving DPP-4 inhibitors, another class of diabetes treatment, and those prescribed RAAS inhibitors, which are commonly used in chronic kidney disease management.
After adjusting for variables such as sex, race, and obesity, GLP-1 users consistently showed a lower risk of requiring dialysis or a kidney transplant over a follow-up period that could extend to five years. The analysis indicated that the protective association persisted across multiple sub-analyses, reinforcing the robustness of the observation.
While the results are promising, the observational nature of the analysis means it cannot prove causation. Researchers noted limitations, including the inability to account for medication adherence, dosage variations, or long-term treatment changes. Nonetheless, the evidence suggests that GLP-1 drugs could provide an additional layer of kidney protection for patients with the illness, particularly those already at risk because of psychiatric medications or metabolic conditions.
The study’s findings align with Mayo Clinic’s Genesis initiative, which emphasizes preventing organ failure and supports multidisciplinary collaborations to identify early markers of decline and intervene before irreversible damage occurs. If further trials confirm these results, they could lead to updated treatment guidelines for the illness, integrating kidney health into psychiatric care plans. For now, the data highlights the need for closer collaboration between psychiatrists, nephrologists, and primary care providers to manage complex patient needs.